United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
FAIL · Does not pass the screen
490.24 USD
At the last full screen 2026-09-03
Screened 2026-09-03 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 490.24 against the desk's fair-value range, base estimate 543.04, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price490.24 USD
Fair value543.04
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markdown545.96-10.2% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
United Therapeutics Corp holds its Markdown at $490.24. Consolidating, no directional conviction, held for 26 days.
As held on the ledger · 2026-09-03
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 26 days
Price at the screen
$490.24
Valuation
17.57 trailing · 16.32 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.56
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
22.55%
Below 33%
Cash held in interest-bearing accounts and securities is 22.5% of assets, under the one-third limit.
Pass
Receivables
24.20%
Below 49%
Money owed to the company is 24.2% of assets, under the 49% limit.
Pass
Revenue purity
6.03%
Below 5%
6.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-03 screen. The gold marker is the market price at the same screen. A 10.8% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +40% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare Disease Treatments Hit Revenue Headwinds
Picture a patient in a clinic waiting for the next dose of an inhaled therapy that keeps a rare lung condition in check. United Therapeutics built its name on exactly those treatments, yet revenue has started to slip by 2 percent while the business still clears a 41 percent profit margin and 20 percent return on equity.
The numbers on paper look orderly, with a forward multiple of 16 times and a narrow moat that keeps some pricing power. Ethical screens are cleared and analysts lean buy, but the flat or falling top line and limited competitive edge leave no real margin of safety worth chasing at current levels.
Risk sits with any further slowdown in prescriptions or fresh competition that could compress those margins faster than the valuation gap suggests. Currency moves and regulatory shifts in specialty drugs add another layer of uncertainty. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UTHR trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-16Markdown$490.24-6.4%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it buy, with a mean price target of $665. Insiders have been net sellers over the past quarter.
2026-08-16Markdown$523.63-4.1%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it buy, with a mean price target of $665.
2026-07-18Markdown$545.96+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (13 analysts) rates it buy, with a mean price target of $665.
2026-07-03Markdown$545.96+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$545.96Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
